Identification of Pathways to Mitigate Immune-Related Adverse Events With Cancer Immunotherapy

Description

This protocol is a prospective, observational study of participants receiving immunotherapy (checkpoint inhibitors, CPI) for cancer therapy, testing the hypothesis that patients with immune related cutaneous adverse events (ircAEs) have unique immunologic endotypes associated with polarized immune responses.

Conditions

Cancer

Talk to us

Study Overview

On this page

Study Details

Study overview

This protocol is a prospective, observational study of participants receiving immunotherapy (checkpoint inhibitors, CPI) for cancer therapy, testing the hypothesis that patients with immune related cutaneous adverse events (ircAEs) have unique immunologic endotypes associated with polarized immune responses.

Identification of Pathways to Mitigate Immune-Related Adverse Events With Cancer Immunotherapy

Identification of Pathways to Mitigate Immune-Related Adverse Events With Cancer Immunotherapy

Condition
Cancer
Intervention / Treatment

-

Contacts and Locations

Denver

National Jewish Health, Denver, Colorado, United States, 80206

Denver

The Melanoma and Skin Cancer Institute, Denver, Colorado, United States, 80206

New York

Memorial Sloan Kettering Cancer Center, New York, New York, United States, 10065

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. Provision of signed and dated informed consent form
  • 2. Stated willingness to comply with all study procedures and availability for the duration of the study
  • 3. Male or female, \>18 yo
  • 4. Diagnosis of solid tumor including, but not limited to, genitourinary/gynecologic, lung, gastrointestinal and melanoma
  • 5. Receiving, or prior to starting on, a checkpoint inhibitor
  • 6. Grade ≥ 2 ircAE (CTCAE v 5.0) (for cohort 1 only)
  • 7. An indication for system corticosteroids or biologic therapies as determined by the treating physician (for cohort 1 only)
  • 8. Life expectancy ≥ 12 weeks
  • 1. Daily use of systemic steroid treatment in the past 4 weeks (prednisone \>10mg a day or equivalent) except for indications other than the cutaneous adverse event, and/or as an anti-emetic pre- or post-chemotherapy infusions.
  • 2. Enrollment in any investigational drug trial with a drug that has not been approved
  • 3. Taking other checkpoint inhibitors beyond anti-PD-(L)-1 or anti-CTLA-4 not yet indicated/approved for use
  • 4. Pregnancy
  • 5. Known blood borne infectious disease
  • 6. Current or pervious diagnosis of a leukemia or lymphoma
  • 7. Unable to give consent for study participation
  • 8. Life expectancy \< 12 weeks
  • 9. Any other condition or diagnosis in the opinion of the investigator that would interfere with the study results

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

National Jewish Health,

Study Record Dates

2025-02